CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)

P. Sharma; B. Escudier; D. F. McDermott; S. George; H. J. Hammers; S. Srinivas; S. S. Tykodi; J. A. Sosman; G. Procopio; E. R. Plimack; D. Castellano; H. Gurney; F. Donskov; P. Bono; J. Wagstaff; T. C. Gauler; T. Ueda; L. A. Xu; I. M. Waxman; R. J. Motzer

doi:10.1016/S0959-8049(16)31926-8

CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)

P. Sharma, B. Escudier, D. F. McDermott, S. George, H. J. Hammers, S. Srinivas, S. S. Tykodi, J. A. Sosman, G. Procopio, E. R. Plimack, D. Castellano, H. Gurney, F. Donskov, P. Bono, J. Wagstaff, T. C. Gauler, T. Ueda, L. A. Xu, I. M. Waxman, R. J. Motzer

Research output: Contribution to journal › Meeting abstract

Original language	English
Pages (from-to)	S708
Number of pages	1
Journal	European Journal of Cancer
Volume	51
Issue number	Supplement 3
DOIs	https://doi.org/10.1016/S0959-8049(16)31926-8
Publication status	Published - Sept 2015
Externally published	Yes
Event	European Cancer Congress - Vienna, Austria Duration: 25 Sept 2015 → 29 Sept 2015

Access to Document

10.1016/S0959-8049(16)31926-8

http://www.ejcancer.com/article/S0959-8049(16)31926-8/fulltext

Cite this

Sharma, P., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Xu, L. A., Waxman, I. M., & Motzer, R. J. (2015). CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). European Journal of Cancer, 51(Supplement 3), S708. https://doi.org/10.1016/S0959-8049(16)31926-8

@article{9530c117015a4f6bb5bf8607f485dda1,

title = "CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)",

author = "P. Sharma and B. Escudier and McDermott, {D. F.} and S. George and Hammers, {H. J.} and S. Srinivas and Tykodi, {S. S.} and Sosman, {J. A.} and G. Procopio and Plimack, {E. R.} and D. Castellano and H. Gurney and F. Donskov and P. Bono and J. Wagstaff and Gauler, {T. C.} and T. Ueda and Xu, {L. A.} and Waxman, {I. M.} and Motzer, {R. J.}",

year = "2015",

month = sep,

doi = "10.1016/S0959-8049(16)31926-8",

language = "English",

volume = "51",

pages = "S708",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier",

number = "Supplement 3",

note = "European Cancer Congress ; Conference date: 25-09-2015 Through 29-09-2015",

}

Sharma, P, Escudier, B, McDermott, DF, George, S, Hammers, HJ, Srinivas, S, Tykodi, SS, Sosman, JA, Procopio, G, Plimack, ER, Castellano, D, Gurney, H, Donskov, F, Bono, P, Wagstaff, J, Gauler, TC, Ueda, T, Xu, LA, Waxman, IM & Motzer, RJ 2015, 'CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)', European Journal of Cancer, vol. 51, no. Supplement 3, pp. S708. https://doi.org/10.1016/S0959-8049(16)31926-8

TY - JOUR

T1 - CheckMate 025

T2 - European Cancer Congress

AU - Sharma, P.

AU - Escudier, B.

AU - McDermott, D. F.

AU - George, S.

AU - Hammers, H. J.

AU - Srinivas, S.

AU - Tykodi, S. S.

AU - Sosman, J. A.

AU - Procopio, G.

AU - Plimack, E. R.

AU - Castellano, D.

AU - Gurney, H.

AU - Donskov, F.

AU - Bono, P.

AU - Wagstaff, J.

AU - Gauler, T. C.

AU - Ueda, T.

AU - Xu, L. A.

AU - Waxman, I. M.

AU - Motzer, R. J.

PY - 2015/9

Y1 - 2015/9

U2 - 10.1016/S0959-8049(16)31926-8

DO - 10.1016/S0959-8049(16)31926-8

M3 - Meeting abstract

SN - 0959-8049

VL - 51

SP - S708

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - Supplement 3

Y2 - 25 September 2015 through 29 September 2015

ER -